Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2014 (2014), Article ID 563812, 7 pages
http://dx.doi.org/10.1155/2014/563812
Research Article

Investigation of PACAP Fragments and Related Peptides in Chronic Retinal Hypoperfusion

1Department of Anatomy, PTE-MTA “Lendulet” PACAP Research Team, University of Pecs, Szigeti ut 12, Pecs 7624, Hungary
2Department of Medical Chemistry, University of Szeged, Dom Ter 8, Szeged 6720, Hungary
3Department of Experimental Zoology and Neurobiology, University of Pecs, Ifjusag Utja 6, Pecs 7624, Hungary
4Department of Ophthalmology, University of Pecs, Nyar Utca 8, Pecs 7624, Hungary
5Department of Sportbiology, University of Pecs, Ifjusag Utja 6, Pecs 7624, Hungary
6Janos Szentagothai Research Center, University of Pecs, Ifjusag Utja 20, Pecs 7624, Hungary

Received 20 January 2014; Accepted 24 March 2014; Published 12 May 2014

Academic Editor: Robert Gabriel

Copyright © 2014 Dora Werling et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Vaudry, A. Falluel-Morel, S. Bourgault et al., “Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 Years after the discovery,” Pharmacological Reviews, vol. 61, no. 3, pp. 283–357, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Reglodi, P. Kiss, K. Szabadfi et al., “PACAP is an endogenous protective factor-insights from PACAP-deficient mice,” Journal of Molecular Neuroscience, vol. 48, pp. 482–492, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Dragich, D. H. Loh, L. M. Wang et al., “The role of the neuropeptides PACAP and VIP in the photic regulation of gene expression in the suprachiasmatic nucleus,” European Journal of Neuroscience, vol. 31, no. 5, pp. 864–875, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Borbely, B. Scheich, Z. Helyes et al., “Neuropeptides in learning and memory,” Neuropeptides, vol. 47, no. 6, pp. 439–450, 2013. View at Google Scholar
  5. M. Tajiri, A. Hayata-Takano, K. Seiriki et al., “Serotonin 5-HT(7) receptor blockade reverses behavioral abnormalities in PACAP-deficient mice and receptor activation promotes neurite extension in primary embryonic hippocampal neurons: therapeutic implications for psychiatric disorders,” Journal of Molecular Neuroscience, vol. 48, no. 3, pp. 473–481, 2012. View at Google Scholar
  6. K. Matsuda, M. Azuma, K. Maruyama, and S. Shioda, “Neuroendocrine control of feeding behavior and psychomotor activity by pituitary adenylate cyclase-activating polypeptide (PACAP) in vertebrates,” Obesity Research & Clinical Practice, vol. 7, no. 1, pp. e1–e88, 2013. View at Google Scholar
  7. S. Bourgault, D. Vaudry, A. Dejda, N. D. Doan, H. Vaudry, and A. Fournier, “Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective peptide,” Current Medicinal Chemistry, vol. 16, no. 33, pp. 4462–4480, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Bourgault, D. Chatenet, O. Wurtz et al., “Strategies to convert PACAP from a hypophysiotropic neurohormone into a neuroprotective drug,” Current Pharmaceutical Design, vol. 17, no. 10, pp. 1002–1024, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Dejda, S. Bourgault, N. D. Doan et al., “Identification by photoaffinity labeling of the extracellular N-terminal domain of PAC1 receptor as the major binding site for PACAP,” Biochimie, vol. 93, no. 4, pp. 669–677, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Yan, X. Zhou, Z. Pan, J. Ma, J. A. Waschek, and E. DiCicco-Bloom, “Pro- and anti-mitogenic actions of pituitary adenylate cyclase-activating polypeptide in developing cerebral cortex: potential mediation by developmental switch of PAC1 receptor mRNA isoforms,” Journal of Neuroscience, vol. 33, no. 9, pp. 3865–3878, 2013. View at Google Scholar
  11. K. Shoge, H. K. Mishima, T. Saitoh et al., “Attenuation by PACAP of glutamate-induced neurotoxicity in cultured retinal neurons,” Brain Research, vol. 839, no. 1, pp. 66–73, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Fabian, D. Reglodi, L. Mester et al., “Effects of PACAP on intracellular signaling pathways in human retinal pigment epithelial cells exposed to oxidative stress,” Journal of Molecular Neuroscience, vol. 48, pp. 493–500, 2012. View at Google Scholar
  13. T. Atlasz, K. Szabadfi, P. Kiss et al., “PACAP-mediated neuroprotection of neurochemically identified cell types in MSG-induced retinal degeneration,” Journal of Molecular Neuroscience, vol. 36, no. 1–3, pp. 97–104, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Endo, T. Nakamachi, T. Seki et al., “Neuroprotective effect of PACAP against NMDA-induced retinal damage in the mouse,” Journal of Molecular Neuroscience, vol. 43, no. 1, pp. 22–29, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Atlasz, K. Szabadfi, P. Kiss et al., “Effects of PACAP in UV-A radiation-induced retinal degeneration models in rats,” Journal of Molecular Neuroscience, vol. 43, no. 1, pp. 51–57, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Seki, H. Itoh, T. Nakamachi, and S. Shioda, “Suppression of ganglion cell death by PACAP following optic nerve transection in the rat,” Journal of Molecular Neuroscience, vol. 36, no. 1–3, pp. 57–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Szabadfi, A. Szabo, P. Kiss et al., “PACAP promotes neuron survival in early experimental diabetic retinopathy,” Neurochemistry International, vol. 64, pp. 84–91, 2014. View at Google Scholar
  18. T. Seki, H. Itoh, T. Nakamachi et al., “Suppression of rat retinal ganglion cell death by PACAP following transient ischemia induced by high intraocular pressure,” Journal of Molecular Neuroscience, vol. 43, no. 1, pp. 30–34, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Atlasz, K. Szabadfi, P. Kiss et al., “Evaluation of the protective effects of PACAP with cell-specific markers in ischemia-induced retinal degeneration,” Brain Research Bulletin, vol. 81, no. 4-5, pp. 497–504, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Atlasz, K. Szabadfi, P. Kiss et al., “Pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects,” Annals of the New York Academy of Sciences, vol. 1200, pp. 128–139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Reglodi, R. Borzsei, T. Bagoly et al., “Agonistic behavior of PACAP6-38 on sensory nerve terminals and cytotrophoblast cells,” Journal of Molecular Neuroscience, vol. 36, no. 1–3, pp. 270–278, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. C. S. Walker, T. Sundrum, and D. L. Hay, “PACAP receptor pharmacology and agonist bias: analysis in primary neurons and glia from the trigeminal ganglia and transfected cells,” British Journal of Pharmacology, vol. 171, pp. 1521–1533, 2014. View at Google Scholar
  23. T. Atlasz, K. Szabadfi, D. Reglodi et al., “Effects of pituitary adenylate cyclase activating polypeptide and its fragments on retinal degeneration induced by neonatal monosodium glutamate treatment,” Annals of the New York Academy of Sciences, vol. 1163, pp. 348–352, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Szabadfi, B. Danyadi, P. Kiss et al., “Protective effects of Vasoactive Intestinal Peptide (VIP) in ischemic retinal degeneration,” Journal of Molecular Neuroscience, vol. 48, pp. 501–507, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Nakamachi, A. Matkovits, T. Seki, and S. Shioda, “Distribution and protective function of pituitary adenylate cyclase-activating polypeptide in the retina,” Endocrinolology (Lausanne), vol. 3, p. 145, 2012. View at Google Scholar
  26. C. Kawaguchi, Y. Isojima, N. Shintani et al., “PACAP-deficient mice exhibit light parameter-dependent abnormalities on nonvisual photoreception and early activity onset,” PLoS ONE, vol. 5, no. 2, article e9286, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Racz, F. Gallyas Jr., P. Kiss et al., “The neuroprotective effects of PACAP in monosodium glutamate-induced retinal lesion involve inhibition of proapoptotic signaling pathways,” Regulatory Peptides, vol. 137, no. 1-2, pp. 20–26, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Szabo, B. Danyadi, E. Bognar et al., “Effect of PACAP on MAP kinases, Akt and cytokine expressions in rat retinal hypoperfusion,” Neuroscience Letters, vol. 523, no. 2, pp. 93–98, 2012. View at Google Scholar
  29. R. Yu, X. Guo, L. Huang, Z. Zeng, and H. Zhang, “The novel peptide PACAP-TAT with enhanced traversing ability attenuates the severe lung injury induced by repeated smoke inhalation,” Peptides, vol. 38, no. 1, pp. 142–149, 2012. View at Google Scholar
  30. N.-D. Doan, D. Chatenet, M. Létourneau, H. Vaudry, D. Vaudry, and A. Fournier, “Receptor-independent cellular uptake of pituitary adenylate cyclase-activating polypeptide,” Biochimica et Biophysica Acta, vol. 1823, no. 4, pp. 940–949, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. N. D. Doan, M. Letourneau, D. Vaudry et al., “Design and characterization of novel cell-penetrating peptides from pituitary adenylate cyclase-activating polypeptide,” Journal of Controlled Release, vol. 163, no. 2, pp. 256–265, 2012. View at Google Scholar
  32. N.-D. Doan, S. Bourgault, A. Dejda et al., “Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects,” Biochemical Pharmacology, vol. 81, no. 4, pp. 552–561, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Dejda, T. Seaborn, S. Bourgault et al., “PACAP and a novel stable analog protect rat brain from ischemia: insight into the mechanisms of action,” Peptides, vol. 32, no. 6, pp. 1207–1216, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. J. M. Muller, C. Debaigt, S. Goursaud et al., “Unconventional binding sites and receptors for VIP and related peptides PACAP and PHI/PHM: an update,” Peptides, vol. 28, no. 9, pp. 1655–1666, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. U. Mathis and F. Schaeffel, “Glucagon-related peptides in the mouse retina and the effects of deprivation of form vision,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 245, no. 2, pp. 267–275, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. A. P. Swedlund and S. A. Rosenzweig, “Characterization of vasoactive intestinal peptide receptors in retina,” Experimental Eye Research, vol. 51, no. 3, pp. 317–323, 1990. View at Publisher · View at Google Scholar · View at Scopus
  37. W. D. Eldred, J. Ammermuller, J. Schechner, U. D. Behrens, and R. Weiler, “Quantitative anatomy, synaptic connectivity and physiology of amacrine cells with glucagon-like immunoreactivity in the turtle retina,” Journal of Neurocytology, vol. 25, no. 5, pp. 347–364, 1996. View at Google Scholar · View at Scopus
  38. E. Diedrich and F. Schaeffel, “Spatial resolution, contrast sensitivity, and sensitivity to defocus of chicken retinal ganglion cells in vitro,” Visual Neuroscience, vol. 26, no. 5-6, pp. 467–476, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. K. A. Vessey, K. A. Lencses, D. A. Rushforth, V. J. Hruby, and W. K. Stell, “Glucagon receptor agonists and antagonists affect the growth of the chick eye: a role for glucagonergic regulation of emmetropization?” Investigative Ophthalmology and Visual Science, vol. 46, no. 11, pp. 3922–3931, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. S. W. M. Koh, A. Kyritis, and G. J. Chader, “Interaction of neuropeptides and cultured glial (Muller) cells of the chick retina: elevation of intracellular cyclic AMP by vasoactive intestinal peptide and glucagon,” Journal of Neurochemistry, vol. 43, no. 1, pp. 199–203, 1984. View at Google Scholar · View at Scopus
  41. R. A. Fanne, T. Nassar, S. N. Heyman, N. Hijazi, and A. A. R. Higazi, “Insulin and glucagon share the same mechanism of neuroprotection in diabetic rats: role of glutamate,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 301, no. 3, pp. R668–R673, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Abu Fanne, T. Nassar, A. Mazuz et al., “Neuroprotection by glucagon: role of gluconeogenesis. Laboratory investigation,” Journal of Neurosurgery, vol. 114, no. 1, pp. 85–91, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. I. P. Y. Lam, F. K. Y. Siu, J. Y. S. Chu, and B. K. C. Chow, “Multiple actions of secretin in the human body,” International Review of Cytology, vol. 265, pp. 159–190, 2008. View at Publisher · View at Google Scholar · View at Scopus